Therefore, any treatment for migraine that targets potassium channel proteins would have to be capable of doing so in an organ-specific manner, so as to minimize extracranial side-effects, either by targeting accessory molecules, proteins, or peptides unique to potassium channels in neuronal tissue or by targeting specific functionality of potassium channels in neuronal tissue. The gene discussed is KCNA3; the disease is migraine disorder.